Aim Immunotech Inc (AIM) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Aim Immunotech Inc   (NYSEAMER: AIM)


Aim Immunotech Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AIM Gross Profit Margin (Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2 		(Mar 31 2025)
Q1
Y / Y Revenue Change 37.5 %
Seq. Revenue Change 4.76 %
Revenue In Millions $0.02
Gross Profit Margin 81.82 %
Gross Profit Margin Total Ranking # 593
Gross Profit In Millions $0.02
Y / Y Gross Profit Change 200 %
Seq. Gross Profit Change -


Commenting First Quarter 2026 Gross Profit Margin
Aim Immunotech Inc achieved Gross Profit of $0 millions compare to Gross Loss of $-0.02 millions recorded in the previous quarter. Revenue increased by 4.76 % Company accomplished above average Gross Profit Margin with 81.82 %.


Observing first quarter 2026 results within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 593.
Learn about Gross Margin
AIM's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 103
Overall # 590

Gross Profit Margin Statistics
High Average Low
84.44 % 57.47 % 30.07 %
(Dec 31 2024)   (Jul 27 2012)


AIM Gross Income Trends • More of AIM's Profitabilty Ratios • AIM Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
AIM's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
AIM's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for AIM's Competitors
Gross Profit Margin Profit Margin for Aim Immunotech Inc 's Suppliers
Gross Profit Margin Profit Margin for AIM's Customers

You may also want to know
AIM's Annual Growth Rates AIM's Profitability Ratios AIM's Asset Turnover Ratio AIM's Dividend Growth
AIM's Roe AIM's Valuation Ratios AIM's Financial Strength Ratios AIM's Gross Profit Growth
AIM's Roa AIM's Inventory Turnover Ratio AIM's Growth Rates AIM's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginMar 31 2026 MRQ Gross ProfitMar 31 2026 MRQ Revenue
Immunocore Holdings Plc  99.59 %$ 106.243  Millions$ 106.677  Millions
Immunitybio inc   99.46 %$ 43.968  Millions$ 44.206  Millions
Invivyd Inc   98.78 %$ 13.576  Millions$ 13.744  Millions
Neurocrine Biosciences Inc   98.31 %$ 800.700  Millions$ 814.500  Millions
Exelixis Inc   96.73 %$ 590.859  Millions$ 610.812  Millions
Biocryst Pharmaceuticals Inc   96.56 %$ 151.036  Millions$ 156.413  Millions
Tarsus Pharmaceuticals Inc   94.20 %$ 152.658  Millions$ 162.054  Millions
Maze Therapeutics Inc   91.04 %$ 18.208  Millions$ 20.000  Millions
Protalix Biotherapeutics inc   87.77 %$ 29.623  Millions$ 33.750  Millions
Pelthos Therapeutics Inc   84.66 %$ 9.233  Millions$ 10.906  Millions
Ginkgo Bioworks Holdings Inc   84.09 %$ 16.376  Millions$ 19.474  Millions
Aim Immunotech Inc   81.82 %$ 0.018  Millions$ 0.022  Millions
Zeo Scientifix Inc   79.62 %$ 2.055  Millions$ 2.581  Millions
Gilead Sciences Inc   79.24 %$ 5,515.000  Millions$ 6,960.000  Millions
Halozyme Therapeutics Inc   78.97 %$ 297.470  Millions$ 376.708  Millions
Novavax inc   78.00 %$ 108.819  Millions$ 139.514  Millions
X4 Pharmaceuticals Inc  77.92 %$ 2.110  Millions$ 2.708  Millions
Humacyte Inc   77.41 %$ 6.982  Millions$ 9.020  Millions
Adaptive Biotechnologies Corporation  73.60 %$ 52.166  Millions$ 70.874  Millions
Biogen Inc   73.32 %$ 1,816.800  Millions$ 2,477.800  Millions
Vericel Corporation  72.00 %$ 49.266  Millions$ 68.425  Millions
Adma Biologics Inc   70.99 %$ 80.750  Millions$ 113.750  Millions
Coherus Oncology inc   69.02 %$ 8.496  Millions$ 12.310  Millions
Amgen Inc   68.16 %$ 5,874.000  Millions$ 8,618.000  Millions
Bio techne Corp  66.91 %$ 208.288  Millions$ 311.288  Millions
Elutia Inc   64.31 %$ 1.802  Millions$ 2.802  Millions
Xtant Medical Holdings Inc   59.94 %$ 11.971  Millions$ 19.971  Millions
Repligen Corp  55.74 %$ 108.284  Millions$ 194.255  Millions
Twist Bioscience Corporation  51.59 %$ 57.122  Millions$ 110.715  Millions
Champions Oncology Inc   50.79 %$ 7.027  Millions$ 13.836  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.